GeoVax Labs, Inc. (NASDAQ:GOVX) Given Consensus Recommendation of “Buy” by Brokerages

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX) have received an average recommendation of “Buy” from the seven research firms that are presently covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $14.20.

A number of research firms recently issued reports on GOVX. HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of GeoVax Labs in a research report on Friday, November 15th. D. Boral Capital reiterated a “buy” rating and set a $18.00 price objective on shares of GeoVax Labs in a research report on Thursday, January 16th. Finally, Alliance Global Partners began coverage on shares of GeoVax Labs in a research report on Monday, November 11th. They set a “buy” rating and a $15.00 price objective for the company.

GeoVax Labs Price Performance

NASDAQ GOVX opened at $1.88 on Friday. GeoVax Labs has a 12-month low of $1.09 and a 12-month high of $11.18. The firm has a 50-day moving average price of $2.38 and a two-hundred day moving average price of $2.75.

GeoVax Labs (NASDAQ:GOVX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.38. The firm had revenue of $2.79 million during the quarter, compared to analyst estimates of $1.84 million. During the same quarter in the previous year, the firm posted ($4.80) earnings per share. On average, research analysts predict that GeoVax Labs will post -4.49 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in GeoVax Labs stock. Virtu Financial LLC bought a new stake in GeoVax Labs, Inc. (NASDAQ:GOVX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned about 0.43% of GeoVax Labs at the end of the most recent reporting period. 6.09% of the stock is currently owned by institutional investors.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.